OPKO Health (OPK) Projected to Announce Earnings on Wednesday

OPKO Health (NASDAQ:OPK) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $136.62 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 3:30 PM ET.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.07. The company had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. During the same quarter in the prior year, the business earned ($0.19) earnings per share. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, analysts expect OPKO Health to post ($0.23) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

OPKO Health Trading Down 1.2%

OPK stock opened at $1.61 on Wednesday. OPKO Health has a twelve month low of $0.98 and a twelve month high of $1.77. The firm’s fifty day simple moving average is $1.55 and its two-hundred day simple moving average is $1.34.

Analyst Upgrades and Downgrades

OPK has been the subject of several analyst reports. UBS Group set a $4.00 target price on shares of OPKO Health in a report on Friday, October 16th. HC Wainwright reiterated a “buy” rating on shares of OPKO Health in a report on Friday, October 16th. Piper Sandler reiterated an “overweight” rating and set a $4.00 price target (up from $3.00) on shares of OPKO Health in a report on Friday, October 16th. Zacks Research raised shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Finally, Barrington Research raised shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price objective for the company in a research note on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $2.96.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.